APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells

Journal of Virology

Volumn 87, Issue 11, 2013, Pages 6492-6506

  Batisse, Julien ^a   Guerrero, Santiago Xavier ^a   Bernacchi, Serena ^a   Richert, Ludovic ^a   Godet, Julien ^a   Goldschmidt, Valérie ^a   Mély, Yves ^a   Marquet, Roland ^a   de Rocquigny, Hugues ^a   Paillart, Jean Christophe ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; VIF PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CONFOCAL MICROSCOPY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FLUORESCENCE LIFETIME IMAGING MICROSCOPY; FLUORESCENCE MICROSCOPY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC TRANSFECTION; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; NONHUMAN; OLIGOMERIZATION; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MULTIMERIZATION; PROTEIN PROTEIN INTERACTION; VIRUS ASSEMBLY; WESTERN BLOTTING; WILD TYPE;

AMINO ACID MOTIFS; CYTIDINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN MULTIMERIZATION; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84878176987     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03494-12     Document Type: Article

References (79)

1. Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R. 2009. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol. Mol. Biol. Rev. 73:211-232.
2. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
3. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. 2004. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23:2451-2458.
4. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94 -98.
5. Blanco-Melo D, Venkatesh S, Bieniasz PD. 2012. Intrinsic cellular defenses against human immunodeficiency viruses. Immunity 37:399-411.
6. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803- 809.
7. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by humanAPOBEC3Gthrough lethal editing of nascent reverse transcripts. Nature 424:99 -103.
8. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L. 2006. The inhibition of tRNALys3-primed reverse transcription by human APOBEC3G during HIV-1 replication. J. Virol. 80:11710 -11722.
9. Holmes RK, Malim MH, Bishop KN. 2007. APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32:118 -128.
10. Mbisa JL, Bu W, Pathak VK. 2010. APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J. Virol. 84:5250 -5259.
11. Chiu YL, Greene WC. 2008. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26:317-353.
12. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285-296.
13. Sodroski J, Goh WC, Rosen C, Tartar A, Portetelle D, Burny A, Haseltine W. 1986. Replicative and cytopathic potential of HTLV-III/ LAV with sor gene deletions. Science 231:1549 -1553.
14. Borman AM, Quillent C, Charneau P, Dauguet C, Clavel F. 1995. Human immunodeficiency virus type 1 Vif mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J. Virol. 69:2058 -2067.
15. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J. 1992. Role of vif in replication of human immunodeficiency virus type 1 inCD4T lymphocytes. J. Virol. 66:6489- 6495.
16. Malim MH, Emerman M. 2008. HIV-1 accessory proteins- ensuring viral survival in a hostile environment. Cell Host Microbe 3:388 -398.
17. Wissing S, Galloway NL, Greene WC. 2010. HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol. Aspects Med. 31:383-397.
18. Liu B, Sarkis PT, Luo K, Yu Y, Yu XF. 2005. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79:9579 -9587.
19. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein bindsthe editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398 -1403.
20. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. 2004. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18:2861-2866.
21. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056 -1060.
22. Jager S, Kim DY, Hultquist JF, Shindo K, Larue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. 2011. Vif hijacks CBF-+ to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375.
23. Zhang W, Du J, Evans SL, Yu Y, Yu XF. 2011. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376 -379.
24. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31.
25. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K. 2007. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81:8236-8246.
26. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. 2003. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77:11398 -11407.
27. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591- 601.
28. Mercenne G, Bernacchi S, Richer D, Bec G, Henriet S, Paillart JC, Marquet R. 2010. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res. 38:633- 646.
29. Henriet S, Sinck L, Bec G, Gorelick RJ, Marquet R, Paillart JC. 2007. Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res. 35:5141- 5153.
30. Batisse J, Guerrero S, Bernacchi S, Sleiman D, Gabus C, Darlix JL, Marquet R, Tisne C, Paillart JC. 2012. The role of Vif oligomerization and RNA chaperone activity in HIV-1 replication. Virus Res. 169:361- 376.
31. Bernacchi S, Henriet S, Dumas P, Paillart JC, Marquet R. 2007. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. J. Biol. Chem. 282:26361-26368.
32. Henriet S, Richer D, Bernacchi S, Decroly E, Vigne R, Ehresmann B, Ehresmann C, Paillart JC, Marquet R. 2005. Cooperative and specific binding of Vif to the 5= region of HIV-1 genomic RNA. J. Mol. Biol. 354:55-72.
33. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. 2000. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J. Virol. 74:8938-8945.
34. Zhang H, Pomerantz RJ, Dornadula G, Sun Y. 2000. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J. Virol. 74:8252- 8261.
35. Kataropoulou A, Bovolenta C, Belfiore A, Trabatti S, Garbelli A, Porcellini S, Lupo R, Maga G. 2009. Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res. 37:3660 -3669.
36. Auclair JR, Green KM, Shandilya S, Evans JE, Somasundaran M, Schiffer CA. 2007. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 69:270 -284.
37. Yang S, Sun Y, Zhang H. 2001. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J. Biol. Chem. 276:4889-4893.
38. Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H. 2003. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 278:6596-6602.
39. Simon JH, Fouchier RA, Southerling TE, Guerra CB, Grant CK, Malim MH. 1997. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J. Virol. 71:5259 -5267.
40. Donahue JP, Vetter ML, Mukhtar NA, D'Aquila RT. 2008. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 377:49 -53.
41. Miller JH, Presnyak V, Smith HC. 2007. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block APOBEC3G incorporation with virions. Retrovirology 4:81. doi:10.1186/1742-4690-4-81.
42. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. 2004. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872.
43. Bergeron JR, Huthoff H, Veselkov DA, Beavil RL, Simpson PJ, Matthews SJ, Malim MH, Sanderson MR. 2010. The SOCS-box of HIV-1 Vif interacts with ElonginBC by induced-folding to recruit its Cul5- containing ubiquitin ligase complex. PLoS Pathog. 6:e1000925. doi:10 .1371/journal.ppat.1000925.
44. Wolfe LS, Stanley BJ, Liu C, Eliason WK, Xiong Y. 2010. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J. Virol. 84:7135- 7139.
45. Bernacchi S, Mercenne G, Tournaire C, Marquet R, Paillart JC. 2011. Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Res. 39:2404 -2415.
46. Fritz JV, Didier P, Clamme JP, Schaub E, Muriaux D, Cabanne C, Morellet N, Bouaziz S, Darlix JL, Mely Y, de Rocquigny H. 2008. Direct Vpr-Vpr interaction in cells monitored by two photon fluorescence correlation spectroscopy and fluorescence lifetime imaging. Retrovirology 5:87. doi:10.1186/1742-4690-5-87.
47. Nguyen KL, Llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, Bour S. 2004. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 319:163-175.
48. Selig L, Pages JC, Tanchou V, Preveral S, Berlioz-Torrent C, Liu LX, Erdtmann L, Darlix J, Benarous R, Benichou S. 1999. Interaction with the p6 domain of the Gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J. Virol. 73:592- 600.
49. Rudner L, Nydegger S, Coren LV, Nagashima K, Thali M, Ott DE. 2005. Dynamic fluorescent imaging of human immunodeficiency virus type 1 Gag in live cells by biarsenical labeling. J. Virol. 79:4055- 4065.
50. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH. 1995. Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J. Virol. 69:4166- 4172.
51. Hassaine G, Courcoul M, Bessou G, Barthalay Y, Picard C, Olive D, Collette Y, Vigne R, Decroly E. 2001. The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein. J. Biol. Chem. 276:16885-16893.
52. Clamme JP, Azoulay J, Mely Y. 2003. Monitoring of the formation and dissociation of polyethylenimine/DNA complexes by two photon fluorescence correlation spectroscopy. Biophys. J. 84:1960 -1968.
53. Pepperkok R, Squire A, Geley S, Bastiaens PI. 1999. Simultaneous detection of multiple green fluorescent proteins in live cells by fluorescence lifetime imaging microscopy. Curr. Biol. 9:269 -272.
54. Merzlyak EM, Goedhart J, Shcherbo D, Bulina ME, Shcheglov AS, Fradkov AF, Gaintzeva A, Lukyanov KA, Lukyanov S, Gadella TW, Chudakov DM. 2007. Bright monomeric red fluorescent protein with an extended fluorescence lifetime. Nat. Methods 4:555-557.
55. Shaner NC, Steinbach PA, Tsien RY. 2005. A guide to choosing fluorescent proteins. Nat. Methods 2:905-909.
56. Simon JH, Malim MH. 1996. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 70:5297-5305.
57. Walker RC, Jr, Khan MA, Kao S, Goila-Gaur R, Miyagi E, Strebel K. 2010. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J. Virol. 84:5201-5211.
58. Techtmann SM, Ghirlando R, Kao S, Strebel K, Maynard EL. 2012. Hydrodynamic and functional analysis of HIV-1 Vif oligomerization. Biochemistry 51:2078 -2086.
59. Farrow MA, Somasundaran M, Zhang C, Gabuzda D, Sullivan JL, Greenough TC. 2005. Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation. AIDS Res. Hum. Retroviruses 21:565-574.
60. Wichroski MJ, Ichiyama K, Rana T. 2005. Analysis of HIV-1 Vifmediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280:8387- 8396.
61. Huvent I, Hong SS, Fournier C, Gay B, Tournier J, Carriere C, Courcoul M, Vigne R, Spire B, Boulanger P. 1998. Interaction and co-encapsidation of human immunodeficiency virus type 1 Gag and Vif recombinant proteins. J. Gen. Virol. 79:1069 -1081.
62. Voss TC, Demarco IA, Day RN. 2005. Quantitative imaging of protein interactions in the cell nucleus. Biotechniques 38:413- 424.
63. Day RN, Periasamy A, Schaufele F. 2001. Fluorescence resonance energy transfer microscopy of localized protein interactions in the living cell nucleus. Methods 25:4 -18.
64. Bouyac M, Courcoul M, Bertoia G, Baudat Y, Gabuzda D, Blanc D, Chazal N, Boulanger P, Sire J, Vigne R, Spire B. 1997. Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J. Virol. 71:9358 -9365.
65. Simon JH, Carpenter EA, Fouchier RA, Malim MH. 1999. Vif and the p55Gag polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J. Virol. 73:2667- 2674.
66. Barraud P, Paillart JC, Marquet R, Tisne C. 2008. Advances in the structural understanding of Vif proteins. Curr. HIV Res. 6:91-99.
67. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK. 2004. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factorinduced depletion. Proc. Natl. Acad. Sci. U. S. A. 101:5652-5657.
68. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. 2004. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U. S. A. 101:3770 -3774.
69. Schrofelbauer B, Chen D, Landau NR. 2004. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U. S. A. 101:3927-3932.
70. Bardy M, Gay B, Pebernard S, Chazal N, Courcoul M, Vigne R, Decroly E, Boulanger P. 2001. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. J. Gen. Virol. 82:2719 -2733.
71. Goncalves J, Jallepalli P, Gabuzda DH. 1994. Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J. Virol. 68:704- 712.
72. Alce TM, Popik W. 2004. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279:34083-34086.
73. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L. 2004. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279: 33177-33184.
74. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF. 2004. Aminoterminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78:11841- 11852.
75. Schafer A, Bogerd HP, Cullen BR. 2004. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328:163-168.
76. Syed F, McCrae MA. 2009. Interactions in vivo between the Vif protein of HIV-1 and the precursor (Pr55GAG) of the virion nucleocapsid proteins. Arch. Virol. 154:1797-1805.
77. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. 2004. Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1:27. doi:10.1186/1742-4690-1-27.
78. Khan MA, Aberham C, Kao S, Akari H, Gorelick R, Bour S, Strebel K. 2001. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol. 75:7252-7265.
79. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79:5870 -5874.